4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics (FDMT) filed a Form 4 reporting that director Shawn Cline Tomasello received an automatic, non-employee director stock-option grant on 06/17/2025.
The award comprises 22,500 stock options with an exercise price of $4.15. Vesting occurs as follows: one-third on 06/17/2026, with the remaining two-thirds vesting in equal monthly installments through 06/17/2028. All options vest immediately upon a change-in-control, and they expire on 06/16/2035. The filing shows 22,500 derivative securities beneficially owned after the transaction. No open-market acquisitions or dispositions of common shares were reported.
4D Molecular Therapeutics (FDMT) – Form 4 filing: Director Charles Theuer received an automatic grant of 22,500 stock options on 17 June 2025 under the company’s non-employee director compensation program.
The options carry a $4.15 exercise price and a 10-year term expiring 16 June 2035. Vesting is staggered: 33% on 17 June 2026, with the balance vesting in equal monthly installments through 17 June 2028. All unvested shares vest immediately if a change-in-control occurs.
After the grant, the reporting person holds 22,500 derivative securities directly. No open-market purchases or sales were reported, and there were no changes in non-derivative holdings. The disclosure is routine and primarily reflects standard director equity compensation designed to align incentives with shareholder interests.
Form 4 filing for 4D Molecular Therapeutics (FDMT) reports a routine non-derivative insider transaction dated 06/17/2025.
- Reporting person: Nancy Miller-Rich, independent director.
- Transaction: Automatic grant of 22,500 stock options (right to buy common shares) at an exercise price of $4.15 per share.
- Vesting schedule: 1/3 vests on 06/17/2026; the remainder vests monthly until fully vested on 06/17/2028, or sooner upon a change-of-control event.
- Expiration: 06/16/2035.
- Post-transaction holdings: 22,500 derivative securities reported as directly held.
No sales or purchases of already-issued common stock occurred, and the filing contains no financial performance data. The grant stems from the company’s standard non-employee director compensation program and does not indicate a shift in corporate strategy or insider sentiment.
Form 4 filed for 4D Molecular Therapeutics, Inc. (FDMT) reports a routine stock-option grant to director John F. Milligan on 06/17/2025. The award covers 33,750 options to purchase common shares at an exercise price of $4.15. The options were automatically granted under the company’s non-employee director compensation program.
Vesting is structured as follows:
- One-third (11,250 options) vests on 06/17/2026
- Remaining options vest in equal monthly installments until fully vested on 06/17/2028
- All options accelerate to full vesting upon a qualifying Change in Control
Following the grant, Milligan beneficially owns 33,750 derivative securities. No open-market purchases or sales of common stock were reported, and there is no cash outlay for the director at grant date. Investors should view this filing as standard governance practice rather than a signal of immediate financial impact.
On June 17, 2025, 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) held its 2025 virtual Annual Meeting of Stockholders. Of the 46.3 million outstanding shares, 38.5 million (≈83%) were represented in person or by proxy.
- Director elections (Proposal 1): All three Class II nominees were re-elected to serve until the 2028 AGM. Support ranged from 84.5% (Dr. Charles P. Theuer) to 98.9% (Susannah Gray).
- Auditor ratification (Proposal 2): Shareholders overwhelmingly confirmed PricewaterhouseCoopers LLP for FY 2025 (≈99.8% in favor).
- Say-on-pay (Proposal 3): 98.7% of votes cast approved FY 2024 executive compensation on an advisory basis.
- Say-on-pay frequency (Proposal 4): A majority (≈99%) selected one-year intervals for future advisory votes; the board will follow this cadence.
No other business or material transactions were reported. The results signal continued shareholder endorsement of the company’s leadership, compensation practices, and external auditor.